EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 338 filers reported holding EXELIXIS INC in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $19,387 | -99.6% | 817 | -99.6% | 0.00% | -100.0% |
Q4 2023 | $4,904,204 | +23.2% | 204,427 | +12.2% | 0.01% | 0.0% |
Q3 2023 | $3,980,218 | +13.7% | 182,161 | -0.6% | 0.01% | +18.2% |
Q2 2023 | $3,501,162 | +464.4% | 183,211 | +473.2% | 0.01% | +450.0% |
Q1 2023 | $620,382 | +24.1% | 31,962 | +2.5% | 0.00% | +100.0% |
Q4 2022 | $500,095 | +23.8% | 31,178 | +21.0% | 0.00% | 0.0% |
Q3 2022 | $404,000 | -27.2% | 25,774 | -3.3% | 0.00% | 0.0% |
Q2 2022 | $555,000 | -41.4% | 26,661 | -36.2% | 0.00% | 0.0% |
Q1 2022 | $947,000 | +19.3% | 41,780 | -3.8% | 0.00% | 0.0% |
Q4 2021 | $794,000 | -17.5% | 43,422 | -4.6% | 0.00% | 0.0% |
Q3 2021 | $962,000 | +398.4% | 45,528 | +330.7% | 0.00% | – |
Q2 2021 | $193,000 | -88.7% | 10,570 | -89.1% | 0.00% | -100.0% |
Q4 2019 | $1,713,000 | -17.7% | 97,226 | -17.4% | 0.01% | -29.4% |
Q3 2019 | $2,081,000 | -13.8% | 117,682 | -4.1% | 0.02% | -19.0% |
Q4 2018 | $2,415,000 | +16.9% | 122,753 | +5.3% | 0.02% | +31.2% |
Q3 2018 | $2,066,000 | -10.9% | 116,588 | +8.2% | 0.02% | -20.0% |
Q2 2018 | $2,318,000 | +7.8% | 107,734 | +11.0% | 0.02% | -9.1% |
Q1 2018 | $2,150,000 | -84.6% | 97,048 | -78.9% | 0.02% | -77.6% |
Q4 2017 | $13,983,000 | +45.6% | 459,959 | +16.0% | 0.10% | +12.6% |
Q3 2017 | $9,604,000 | +53.3% | 396,361 | +55.9% | 0.09% | +33.8% |
Q2 2017 | $6,263,000 | +128.1% | 254,280 | +100.7% | 0.06% | +103.1% |
Q1 2017 | $2,746,000 | +524.1% | 126,727 | +8.3% | 0.03% | +433.3% |
Q2 2015 | $440,000 | -61.1% | 117,008 | -73.4% | 0.01% | -66.7% |
Q1 2015 | $1,132,000 | +708.6% | 440,583 | +965.4% | 0.02% | +800.0% |
Q2 2014 | $140,000 | -77.2% | 41,354 | -76.1% | 0.00% | -80.0% |
Q1 2014 | $613,000 | +50.6% | 173,083 | +160.4% | 0.01% | +66.7% |
Q4 2013 | $407,000 | -13.4% | 66,470 | -17.7% | 0.01% | -33.3% |
Q3 2013 | $470,000 | +61.0% | 80,798 | +25.4% | 0.01% | +28.6% |
Q2 2013 | $292,000 | – | 64,419 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |